Abstract
BACKGROUND: Breast cancer (BC) in young women is uncommon and often more aggressive. There are disparities in terms of screening coverage, diagnostic features and access to optimal treatment among young BC patients worldwide. To better understand this scenario through real world data we performed a sub-analysis of AMAZONA III study. METHODS: The AMAZONA III study (GBECAM 0115) is a prospective registry that included 2950 women newly diagnosed with invasive BC in Brazil during the period of January 2016 to March 2018 within 22 sites. Of them, 2888 patients had valid data regarding age at diagnosis and complete baseline information. For the purpose of comparisons of epidemiologic and clinicopathologic features at the time of diagnosis of BC, patients were divided in two groups: women aged ≤40 years (Group 1) and >40 years (Group 2). Quantitative variables were expressed with mean, while categorical variables were described as their count and percentage and compared using the chi-square test. RESULTS: Of 2888 women, 486 (17%) were ≤40 years of age. No differences were found between ethnicity, performance status, body mass index, personal income, health insurance and family history of cancer between the two groups. Young women had higher educational level (p<0.001), were more involved into a labor activity (p<0.001) and were more frequently married (p<0.001). There were also significant differences regarding nulliparity (p<0.001) and previous use of oral contraceptives (p<0.001). Mode of detection of BC was symptomatic in 73.4% of young group versus 64.5% in older group and screen-detected was only 26.6% vs. 35.5% respectively (p<0.001). Table 1 describes clinicopathological characteristics of the two groups. Young women presented more frequently with stage III,T3/T4, Grade 3 tumors and HER-2 positive, Luminal B and triple negative subtypes. Women older than 40 years had more stage I, Luminal A and Grade 1/2 tumors. CONCLUSION: Brazilian women under the age of 40 have unfavorable clinicopathological features of BC at diagnosis with more aggressive subtypes and advanced stage compared with older women. No differences in socioeconomic and ethnical aspects were found but a higher percentage of young women had symptomatic detection of BC which could explain the later stage of disease at diagnosis. Young women were economically active and the majority married which highlights the socioeconomic impact of this disease in Brazil.
Information . | Group 1 (≤40 years) | Group 2 (> 40 years) | p-value |
---|---|---|---|
N: 2888 | 486 (16.83%) | 2402 (83.17%) | |
Stage at diagnosis | p< 0.001 | ||
I | 76 (19.2%) | 541 (27.8%) | |
II | 156 (39.4%) | 816 (41.9%) | |
III | 146 (36.8%) | 489 (25.1%) | |
IV | 19 (4.6%) | 101 (5.2%) | |
Tumor size | p< 0.001 | ||
T1 | 114 (27.1%) | 749 (36.9%) | |
T2 | 141 (33.6%) | 764 (37.6%) | |
T3 | 101 (24.1%) | 282 (13.9%) | |
T4 | 64 (15.2%) | 235 (11.6%) | |
Tumor grade | p < 0.001 | ||
Grade 1 | 46 (10.7%) | 381 (17.9%) | |
Grade 2 | 198 (46.2%) | 1150 (52.0%) | |
Grade 3 | 185 (43.1%) | 641 (30.1%) | |
Molecular Subtype | p < 0.001 | ||
Luminal A | 106 (30.6%) | 957 (51.3%) | |
Luminal B - HER 2 negative | 55 (15.8%) | 212 (11.4%) | |
Luminal B- HER 2 positive | 79 (22.8%) | 298 (16.0%) | |
HER 2 positive | 27 (7.8%) | 135 (7.2%) | |
Triple negative | 80 (23.0%) | 264 (14.1%) |
Information . | Group 1 (≤40 years) | Group 2 (> 40 years) | p-value |
---|---|---|---|
N: 2888 | 486 (16.83%) | 2402 (83.17%) | |
Stage at diagnosis | p< 0.001 | ||
I | 76 (19.2%) | 541 (27.8%) | |
II | 156 (39.4%) | 816 (41.9%) | |
III | 146 (36.8%) | 489 (25.1%) | |
IV | 19 (4.6%) | 101 (5.2%) | |
Tumor size | p< 0.001 | ||
T1 | 114 (27.1%) | 749 (36.9%) | |
T2 | 141 (33.6%) | 764 (37.6%) | |
T3 | 101 (24.1%) | 282 (13.9%) | |
T4 | 64 (15.2%) | 235 (11.6%) | |
Tumor grade | p < 0.001 | ||
Grade 1 | 46 (10.7%) | 381 (17.9%) | |
Grade 2 | 198 (46.2%) | 1150 (52.0%) | |
Grade 3 | 185 (43.1%) | 641 (30.1%) | |
Molecular Subtype | p < 0.001 | ||
Luminal A | 106 (30.6%) | 957 (51.3%) | |
Luminal B - HER 2 negative | 55 (15.8%) | 212 (11.4%) | |
Luminal B- HER 2 positive | 79 (22.8%) | 298 (16.0%) | |
HER 2 positive | 27 (7.8%) | 135 (7.2%) | |
Triple negative | 80 (23.0%) | 264 (14.1%) |
Citation Format: Franzoi MA, Rosa D, Barrios C, Bines J, Cronemberger E, Queiroz G, Cordeiro de Lima VC, Junior R, Couto J, Emerenciano K, Resende H, Crocamo S, Reinert T, Van Evyl B, Neron Y, Dybal V, Lazaretti N, Costamilan RdC, de Andrade D, Mathias C, Zerwes Vacaro G, Borges G, Silva K, Werutsky G, Morelle A, Sampaio Filho CA, Mano M, Zaffaroni F, Simon S, Liedke PE. Advanced stage at diagnosis and worse clinicopathologic features in young woman with breast cancer. A sub-analysis of Brazilian population through the AMAZONA III study (GBECAM 0115) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-08-27.